ArticleBrain : a journal of neurology2019

Reply: Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis.

Yves Allenbach et al.PubMed ↗Publisher ↗

No numbers read from the abstract.